James L. Abbruzzese
Duke University
623 Papers
9.4K Citations
James L. Abbruzzese is an academic researcher from Duke University. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 117, co-authored 609 publications. Previous affiliations of James L. Abbruzzese include Mansoura University & University of California, San Francisco.
Chat about Author
Papers
•Journal Article
Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668
Darren W. Davis,Ryan K. Takamori,Chandrajit P. Raut,Henry Q. Xiong,Roy S. Herbst,Walter M. Stadler,John V. Heymach,George D. Demetri,Asif Rashid,Yu Shen,Sijin Wen,James L. Abbruzzese,David J. McConkey +12 more
TL;DR: Substantial inhibition of tumor microvessel density and growth and increased apoptosis were observed at SU6668 maximum tolerated dose (100 mg/kg) in L3.6pl pancreatic tumors and neither drug produced marked biological activity in primary patient tumors.
43
Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy
TL;DR: Assessment of the response rate, duration of response, and type, severity and reversibility of toxicities in patients with Stage IV adenocarcinoma of the pancreas treated with docetaxel could allow for the identification of a subgroup of patients with a higher rate of response to docetAXel.
42
A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy.
TL;DR: A metastatic model of Panc02 murine pancreatic adenocarcinoma implanted into the pancreas of syngeneic C57BL/6 mice should be a valuable tool for investigating the molecular mechanisms governing pancreatic cancer growth and metastasis and exploring potential treatment modalities for this disease.
42
Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions.
TL;DR: Gemcitabine in combination with cytotoxic agents or molecular targeted agents hold promise and the search for effective therapy for advanced pancreatic cancer continues.
41
Carcinoma of Unknown Primary
Gauri R. Varadhachary,Renato Lenzi,Martin N. Raber,James L. Abbruzzese +3 more
- 01 Jan 2001
TL;DR: Despite the sophisticated diagnostic tools available to establish the diagnosis of human neoplasia, oncologists frequently are asked to evaluate and treat a subset of patients with metastatic cancer in whom detailed investigations fail to identify a primary anatomic site.
41